Abstract 1585P
Background
The IVY study (UMIN000033376) investigated the impact of first-line platinum-induced PN on the incidence of PN during second-line PTX-based chemotherapy and its efficacy in patients with unresectable AGC.
Methods
The study utilized the Common Terminology Criteria for Adverse Events (CTCAE), the Patient Neurotoxicity Questionnaire (PNQ), and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) to assess PN. The primary endpoint was to determine the incidence of grade 3 or greater PN during second-line treatment in patients with and without PN at the start of treatment. The secondary objective was to examine the relationship between PN and the efficacy.
Results
Of 162 patients enrolled in this study, 156 received second-line PTX-based chemotherapy and were divided into two groups based on their PN status at the start of the treatment. The characteristics of 156 patients are as follows: the median age was 69 years, 72% were male, 90% were ECOG PS: 0 or 1, 81% used oxaliplatin in their first-line chemotherapy regimen. Of the 156 patients, 90 patients (58%) were in the group with PN (CTCAE grade: 1 to 3), and 66 were in the group without PN (grade: 0). The group with PN had a higher incidence of grade 3 or greater PN than the group without PN (16.7% vs. 4.6%, p=0.02). The progression-free survival and the overall response rate were not significantly different between the two groups (4.0 months in the group with PN vs. 3.5 months without PN, p=0.20; and 23% vs. 19%, p=0.69). However, the median overall survival was significantly better in the group with PN (10.3 months vs. 8.1 months, p=0.04). The quality-of-life scores, as assessed by PNQ and FACT/GOG-Ntx, were lower in the group with PN than the scores of the group without PN during two months of treatment.
Conclusions
Starting second-line PTX-based chemotherapy with existing PN increased the severity of PN during treatment. However, this adverse effect did not impact the effectiveness of second-line PTX-based chemotherapy for patients with unresectable AGC.
Clinical trial identification
UMIN000033376.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Ando: Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical Co., Ltd.; Financial Interests, Institutional, Invited Speaker: Otsuka Pharmaceutical Co., Ltd., Taiho, Daiichi Sankyo Company, Limited., Nippon Kayaku Co.,Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22